44th Annual Albert M. Biele, MD, Memorial Lecture: The Rise and Fall of the Dopamine Hypothesis as the Basis of the Pharmacologic Treatment of Schizophrenia

Authors

Peter J. Weiden, MD, Stony Brook University

Document Type

Presentation

Publication Date

12-13-2023

Comments

Presentation: 1:11:03

Abstract

Learning Objectives

• Present the rise of the dopamine hypothesis dating back to the 1960s, its evolution of the last 70 years and its positive contributions to improving available treatments for schizophrenia
• Show the downside relying on the dopamine hypothesis for psychopharmacology of schizophrenia given the limitations of current treatments and how it has led to complacency among clinicians and researchers looking for alternative approaches
• Present clinical data of investigational medications that completely bypass D₂ affinity that meet all efficacy criteria for treating schizophrenia
• Muscarinic receptor agonists are further along but it is likely other approaches will follow. The presentation will give some examples as to advances in drug development that are likely to benefit patients with schizophrenia in the near future

Recommended Citation

Weiden, MD, Peter J., "44th Annual Albert M. Biele, MD, Memorial Lecture: The Rise and Fall of the Dopamine Hypothesis as the Basis of the Pharmacologic Treatment of Schizophrenia" (2023). Department of Psychiatry and Human Behavior Grand Rounds. Paper 68.
https://jdc.jefferson.edu/phbgr/68

Language

English